Abstract
Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors. Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics. To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7). Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90% at standard clinical doses. There was no significant difference between occupancy levels obtained with haloperidol or risperidone. Drug-induced parkinsonism was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%. Based on these observations, it is concluded that 5-HT2 blockade obtained with risperidone at D2 occupancy rates of 60% and above does not appear to protect against the risk for extrapyramidal side effects.
Original language | English (US) |
---|---|
Pages (from-to) | 91-101 |
Number of pages | 11 |
Journal | Psychiatry Research - Neuroimaging |
Volume | 75 |
Issue number | 2 |
DOIs | |
State | Published - Sep 29 1997 |
Externally published | Yes |
Keywords
- Antipsychotics
- I-123-IBZM
- Neuroleptics
- SPECT
- Schizophrenia
ASJC Scopus subject areas
- Neuroscience (miscellaneous)
- Radiology Nuclear Medicine and imaging
- Psychiatry and Mental health